23 Jul, 2026
According to Straits Research, the global cancer biopsy market, valued at $33.38 billion in 2025, is projected to grow from $35.98 billion in 2026 to $65.67 billion by 2034 at a CAGR of 7.81% during the forecast period 2026–2034.
A biopsy is a procedure where a small amount of tissue is extracted for examination under a microscope. In the case of a core biopsy, radiologists employ a needle to extract a sample from the lung tumor for diagnostic purposes. In this technique, the healthcare provider frequently employs a chest CT scan or a specialized X-ray machine to precisely direct the needle. Research studies have determined that CT-guided core needle biopsies are a comparatively safer and well-established method for obtaining tumor samples with a higher yield than traditional biopsies, particularly for detecting EGFR mutation during screening.
In the upcoming years, the liquid biopsy market is predicted to grow significantly, primarily driven by biopharmaceutical manufacturers and genomic data analysis companies. These companies are expected to make growing investments and implement strategic initiatives. In early 2018, Seven Bridges Genomics, a company specializing in biomedical data analysis, revealed its intention to venture into the liquid biopsy market. These emerging companies are likely to collaborate with established participants in the liquid biopsy industry, such as SOPHiA Genetics, QIAGEN Bioinformatics, Agilent Technologies, and Fabric Genomics. This trend is anticipated to further support the overall expansion of the cancer biopsy market.
The significance of cancer diagnostic tests is paramount for healthcare professionals, doctors, and physicians in order to develop tailored therapeutic strategies for individual patients. Payments related to cancer tests are crucial for patients diagnosed with cancer or exhibiting a predisposition to cancer. As a result, commercial manufacturers and new market players are increasingly prioritizing the development of top-notch cancer testing solutions. This trend offers a profitable opportunity to grow the cancer biopsy industry. Moreover, the rising demand for liquid biopsy-based diagnostics can be primarily attributed to a heightened focus on the affordability and accuracy of cancer diagnostic testing.
North America is the most significant global cancer biopsy market shareholder and is expected to expand substantially during the forecast period. Due to the substantial contribution of the U.S., the region is anticipated to sustain its dominant position throughout the projected period. Companies in this area primarily focus on developing and distributing innovative kits with applications for quick diagnostics. Moreover, the profitable tactics that the relevant government agencies have recommended have greatly contributed to the growing use of liquid biopsies in the United States. The FDA recently developed a framework that serves as the cornerstone for regulatory initiatives pertaining to liquid biopsy-based oncology diagnostics. Companion diagnostics, approval precedents, and enrichment biomarkers are all governed by this framework. The FDA approved the Clinical Laboratory Improvement Amendment-created tests, which have improved the liquid biopsy regulatory pathways.
sales@straitsresearch.com